After a brief introduction, Lyudmila Bazhenova, MD reviews treatment options for early-stage NSCLC, the prevalence of EGFR mutations, and guidelines for managing patients with stage 1b resectable disease.
Back
EGFR Mutant NSCLC: Expert Perspectives in Testing and Targeted Therapy
Moderator Zofia Piotrowska, MD, MHS introduces an upcoming Onclive Peer Exchange discussion with expert panelists concerning recent updates from in the diagnosis and treatment of EGFR Mutant NSCLC.
EGFR Mutant NSCLC: Expert Perspectives in Testing and Targeted Therapy
Episodes
All
All
The panelists explore the groundbreaking ADAURA trial, covering its study design, efficacy and safety results, and the current clinical implications.
Analyzing a recent overall survival analysis from the ADAURA trial, its impact on practice, and changes in the treatment landscape of early NSCLC.
Recommendations for community oncologists concerning molecular testing, including the types of tests, timing best practices, and how the results should inform treatment decisions.
On the subject of patient eligibility, the panel deliberates on the decision-making process between osimertinib and chemotherapy and outlines adjuvant therapy options.
Insights on the use of neoadjuvant therapy in resectable NSCLC, particularly focusing on the use of neoadjuvant IO in EGFR mutated patients and the results of relevant trials.
Advertisement
Advertisement
Trending on OncLive
1
Five Under 5: Top Oncology Videos for the Week of 8/31/26
2
FDA Approves Camizestrant Plus a CDK4/6 Inhibitor for Emergent ESR1-Mutated HR+, HER2– Advanced Breast Cancer
3
B7-H4–Targeted ADCs Signal a New Frontier for Platinum-Resistant Ovarian and Endometrial Cancer
4
Ivonescimab Meets OS End Point vs Pembrolizumab in First-Line PD-L1+ NSCLC
5